

Please note that these slides were created during the earlier development phase.

Details are subject to change and should not be applied without confirmation.

# PCORnet ADAPTABLE Data Strategy Discussion

***Friday, October 30, 2015***


*Hosted by Lesley Curtis, PhD  
and Schuyler Jones, MD*

*Facilitated by Shelley Rusincovitch  
and Lisa Eskenazi*



**Adaptable**

The Aspirin Study



# Welcome & Overview


# Prior discussions

---

- 📍 Phenotype working session held on September 4, 2015
  - Slides, recording, and summary:  
<https://pcornet.centraldesktop.com/p/ZgAAAAAAZgS3>
- 📍 Data strategy session held on September 25, 2015
  - Slides, recording, and summary:  
<https://pcornet.centraldesktop.com/p/ZgAAAAAAZn7T>

# Protocol and informed consent

---

 Protocol and consent are finalized as of October 22

- Publically posted on PCORnet.org:  
<http://www.pcornet.org/aspirin/>
- Protocol: [www.pcornet.org/wp-content/uploads/2015/10/ADAPTABLE-Final-Protocol-Vers-1-Oct-22-2015.pdf](http://www.pcornet.org/wp-content/uploads/2015/10/ADAPTABLE-Final-Protocol-Vers-1-Oct-22-2015.pdf)
- Consent: [www.pcornet.org/wp-content/uploads/2015/04/ADAPTABLE-Consent-Form\\_2015-10-22-FINAL.pdf](http://www.pcornet.org/wp-content/uploads/2015/04/ADAPTABLE-Consent-Form_2015-10-22-FINAL.pdf)

# Setting the stage for today's meeting

---

Our scope for today:

- Discuss the current status of development for the ADAPTABLE data components
- Outline considerations and areas needing further assessment

# Setting the stage for today's meeting (2)

---

Important context:

- Contracting is not yet executed
- Given this state, today's conversation is not intended to assign tasks or effort for networks; however, networks may choose to “work ahead” if they feel appropriate

# Final caveat


---

- 🔴 We'll be talking today about the current state of development
- 🔴 These details may change during the iterative design, development, and implementation of the project



# Base Phenotype Specification

# Potential Participant Pool



# Screening and recruitment development

---

- 📍 Sites and/or networks are heterogeneous, and expected to have different processes for identifying, contacting, and inviting potential trial participants
  - “Base phenotype” (to be developed by ADAPTABLE CC) will be modifiable by individual sites to best suit their processes

# ADAPTABLE eligibility criteria

ADAPTABLE Protocol  
Final Version 1.0,  
October 22, 2015,  
section III.A.1., pages  
16-17 (PDF pages 20-  
21).

[This image altered to  
remove page break.]

*Ticagrelor criterion  
was added as a  
result of protocol  
comment cycle*

1. Known atherosclerotic cardiovascular disease (ASCVD), defined by a history of prior myocardial infarction, prior coronary angiography showing  $\geq 75\%$  stenosis of at least one epicardial coronary vessel, or prior coronary revascularization procedures (either PCI or CABG)
2. Age  $\geq 18$  years
3. No known safety concerns or side effects considered to be related to aspirin, including
  - a. No history of significant allergy to aspirin such as anaphylaxis, urticaria, or significant gastrointestinal intolerances
  - b. No history of significant GI bleed within the past 12 months
  - c. Significant bleeding disorders that preclude the use of aspirin
4. Access to the Internet. In the event that the CDRNs are notified that a cohort of patients without internet access can be included, then patient agreement will be obtained during the consent process to provide follow-up information by telephone contact with the DCRI Call Center.
5. Not currently treated with an oral anticoagulant – either warfarin or a novel anticoagulant (dabigatran, rivaroxaban, apixaban, edoxaban) – and not planned to be treated in the future with an oral anticoagulant for existing indications such as atrial fibrillation, deep venous thrombosis, or pulmonary embolism.
6. Not currently treated with ticagrelor and not planned to be treated in the future with ticagrelor.
7. Female patients who are not pregnant or nursing an infant
8. Estimated risk of a major cardiovascular event (MACE)  $> 8\%$  over next 3 years as defined by the presence of at least one or more of the following enrichment factors:
  - a. Age  $> 65$  years
  - b. Serum creatinine  $> 1.5$  mg/dL
  - c. Diabetes mellitus (Type 1 or Type 2)
  - d. 3-vessel coronary artery disease
  - e. Cerebrovascular disease and/or peripheral arterial disease
  - f. Left ventricular ejection fraction (LVEF)  $< 50\%$
  - g. Current cigarette smoker

# ADAPTABLE eligibility criteria contain both inclusions and exclusions

There will be no exclusions for any upper age limit, comorbid conditions, or concomitant medications other than oral anticoagulants and ticagrelor that are used at the time of randomization, or are planned to be used during the study follow-up.

Simple, inclusive eligibility criteria will make enrollment easier, and will render study results more generalizable to a broader population of patients. We will exclude pregnant or lactating women (because of concern for the fetus or child), patients taking oral anticoagulants or likely to require an oral anticoagulant during trial follow-up (because of complex drug interactions and a projected excessive risk of bleeding), and patients at relatively low risk for cardiovascular events (ie, no enrichment factor because of the large number of outcomes needed to detect a clinically meaningful difference with the available sample size).

ADAPTABLE Protocol Final Version 1.0, October 22, 2015, section III.A.1., page 17 (PDF page 21).

# Base phenotype customization is expected

## *III.A.3.b. Cohort Identification*

Local site investigators within the CDRNs will be asked to endorse the protocol. They will then be asked to give their permission for the CDRN, through its integrated health system members, to identify and contact potentially eligible patients. In the latter case, patients who meet criteria for secondary prevention after a cardiovascular event will be identified using search algorithms developed by the DCRI Coordinating Center (based on the trial inclusion criteria) and customized by the CDRN for their own EHR systems. Broad agreement from both cardiovascular specialists and primary care physicians will be sought. In this trial, we believe that most systems will agree that prior approval of the relevant clinician will be needed and useful since these patients will be at high-risk for death or a major disabling event. Although it is unlikely that a medical reason for ineligibility will be found, most of these patients are close to their clinicians, whose confidence in and support of the trial will be important for patient engagement, both in terms of participation as well as promoting adherence to the study medication and treatment of the inevitable clinical events.

# Feedback cycle for base phenotype specification

---

- 📍 Use of process developed for CDM review cycles
- 📍 Cycle to open on **Tuesday, November 3** via e-mail
- 📍 Excel spreadsheet template for comments
- 📍 **One spreadsheet response per network requested**
- 📍 How will your network plan to document your full specification?

# **Walk through draft specification**




# Open discussion: Phenotype development

---

- 📍 Thoughts on defining populations in line with minimal risk
- 📍 Validating phenotype performance, including the use of spot checking
- 📍 What are other areas?


# ADAPTABLE RDBMS and SAS Platform Basis

# Modules of the data landscape amalgamate into the study database



# Recommended setup\* for ADAPTABLE data partners - DRAFT

\* Please note that data partners are known to be heterogeneous in their technical configurations and processes.




# Open Discussion

---

- 📍 Network-specific data refresh processes
- 📍 Other questions or thoughts?

# Data Flow Development between Patient Portal and Sites

# Steps to Randomize Participants



# CDRN Responsibilities



- ❖ CDRNs request “Golden Ticket” codes through Mytrus
- ❖ CDRNs invite potential participants and provide each a “Golden Ticket”
- ❖ CDRNs track “Golden Ticket” assignments
- ❖ Mytrus provides “Golden Ticket” status for those entered into Mytrus
- ❖ CDRNs reconcile “Golden Ticket” to patient identifiers
- ❖ CDRNs update PCORNET\_TRIAL (including the PARTICIPANTID and TRIAL\_INVITE\_CODE)



# Golden Ticket



# Mytrus Subject ID



# Participant Identifiers

ID	Origin	Trigger	Description
Golden Ticket	Mytrus	CDRNs request through Mytrus	CDRNs request as bulk and receive download that can be used for mail merges
Mytrus Subject ID	Mytrus	Upon randomization	Unique system generated study number assigned at randomization and sequential
PATID	PCORNET CDM	Present in the CDM	The unique subject identifier in the PCORNET CDM that CDRNs populate in PCORNET_TRIAL
PARTICIPANTID	PCORNET_TRIAL	CDRN Populates	The ADAPTABLE randomized participant identifier that links the Mytrus randomized participants to the PCORNET CDM
TRIAL_INVITE_CODE	PCORNET_TRIAL	CDRN Populates	The ADAPTABLE invited participant identifier captured in PCORNET_TRIAL

# Mytrus Reports

- Entered “Golden Ticket” Codes
- I/E Dropped Out (*aggregate*)
- Completed Account Creation
- Signed Consent
- Randomized
- Key Participant Identifiers (e.g. Name, DOB, Gender, Race)
- Other fields needed for PCORNET\_TRIAL

PCORNET_TRIAL
PATID
TRIALID
PARTICIPANTID
TRIAL_SITEID
TRIAL_ENROLL_DATE
TRIAL_END_DATE
TRIAL_WITHDRAW_DATE
TRIAL_INVITE_CODE

Associations with  
PCORnet clinical trials

# Open discussion

---

- 📍 CDRN planning for integration back into medical record
- 📍 Other thoughts?

# Next steps

---

- ❖ Materials from this meeting to be posted and shared
  - PCORnet weekly updates e-mail will be important mechanism to monitor
  - Supplementary DRNOC and Workgroups blog:  
<https://pcornet.centraldesktop.com/drnoc-workgroups/blog/>
- ❖ Feedback cycle for base phenotype draft
- ❖ Contracting, site operations, and startup
  - Biweekly CDRN Calls, Mondays at 2 PM

# Reference Slides

# Abbreviations

---

- CDM = Common Data Model (<http://pcornet.org/resource-center/pcornet-common-data-model/>)
- DCRI = Duke Clinical Research Institute, the ADAPTABLE Coordinating Center
- DRN = Distributed Research Network
- DSMB = Data and Safety Monitoring Board
- DSSNI = Data Standards, Security, and Network Infrastructure
- LTFU = Lost to Follow-up
- RDBMS = Relational Database Management System (for example, Oracle, SQL Server, PostgreSQL, MySQL)

**ADAPTABLE  
Trial**

**Obesity  
Observational  
Studies**

**Future Trials  
and Studies**

**PCORnet Distributed Research Network (DRN)  
Data Infrastructure**

**(part of the PCORnet Coordinating Center)**

The ADAPTABLE trial is based upon the foundation of the PCORnet DRN data infrastructure. PCORnet trials and studies form a continuous cycle of improvement in data infrastructure development.



# Why are “sites” different from “datamarts”?

---


Working definitions:

Sites = **Organization of people** for clinical and patient-facing purposes.

Datamarts = **Organization of data** for distributed querying activity.

- ❖ Existing CDRNs have different network typologies (ie, different configurations for their datamarts)
  - One datamart may include more than one site
- ❖ Sites participating in ADAPTABLE will likely be smaller components of larger networks

# How it all comes together for analysis (draft version)



# PCORnet Common Data Model v3.0

New to v3.0

## DEMOGRAPHIC

**PATID**  
BIRTH\_DATE  
BIRTH\_TIME  
SEX  
HISPANIC  
RACE  
BIOBANK\_FLAG

Fundamental basis

## ENROLLMENT

**PATID**  
**ENR\_START\_DATE**  
ENR\_END\_DATE  
CHART  
**ENR\_BASIS**

## DISPENSING

**DISPENSINGID**  
**PATID**  
PRESCRIBINGID (optional)  
**DISPENSE\_DATE**  
NDC  
DISPENSE\_SUP  
DISPENSE\_AMT

## DEATH

**PATID**  
**DEATH\_DATE**  
DEATH\_DATE\_IMPUTE  
**DEATH\_SOURCE**  
DEATH\_MATCH\_CONFIDENCE

## DEATH\_CONDITION

**PATID**  
**DEATH\_CAUSE**  
**DEATH\_CAUSE\_CODE**  
**DEATH\_CAUSE\_TYPE**  
**DEATH\_CAUSE\_SOURCE**  
DEATH\_CAUSE\_CONFIDENCE

Data captured from processes associated with healthcare delivery

## VITAL

**VITALID**  
**PATID**  
ENCOUNTERID (optional)  
**MEASURE\_DATE**  
MEASURE\_TIME  
**VITAL\_SOURCE**  
HT  
WT  
DIASTOLIC  
SYSTOLIC  
ORIGINAL\_BMI  
BP\_POSITION  
**SMOKING**  
TOBACCO  
TOBACCO\_TYPE

## CONDITION

**CONDITIONID**  
**PATID**  
ENCOUNTERID (optional)  
REPORT\_DATE  
RESOLVE\_DATE  
**ONSET\_DATE**  
CONDITION\_STATUS  
**CONDITION**  
**CONDITION\_TYPE**  
**CONDITION\_SOURCE**

## PRO\_CM

**PRO\_CM\_ID**  
**PATID**  
ENCOUNTERID (optional)  
**PRO\_ITEM**  
PRO\_LOINC  
**PRO\_DATE**  
PRO\_TIME  
**PRO\_RESPONSE**  
PRO\_METHOD  
PRO\_MODE  
PRO\_CAT

Data captured within multiple contexts: healthcare delivery, registry activity, or directly from patients

## ENCOUNTER

**ENCOUNTERID**  
**PATID**  
**ADMIT\_DATE**  
ADMIT\_TIME  
DISCHARGE\_DATE  
DISCHARGE\_TIME  
PROVIDERID  
FACILITY\_LOCATION  
**ENC\_TYPE**  
FACILITYID  
DISCHARGE\_DISPOSITION  
DISCHARGE\_STATUS  
DRG  
DRG\_TYPE  
ADMITTING\_SOURCE

## DIAGNOSIS

**DIAGNOSISID**  
**PATID**  
**ENCOUNTERID**  
*ENC\_TYPE (replicated)*  
*ADMIT\_DATE (replicated)*  
*PROVIDERID (replicated)*  
**DX**  
**DX\_TYPE**  
**DX\_SOURCE**  
PDX

## PROCEDURES

**PROCEDURESID**  
**PATID**  
**ENCOUNTERID**  
*ENC\_TYPE (replicated)*  
*ADMIT\_DATE (replicated)*  
*PROVIDERID (replicated)*  
PX\_DATE  
**PX**  
**PX\_TYPE**  
PX\_SOURCE

Data captured from healthcare delivery, direct encounter basis

## LAB\_RESULT\_CM

**LAB\_RESULT\_CM\_ID**  
**PATID**  
ENCOUNTERID (optional)  
LAB\_NAME  
SPECIMEN\_SOURCE  
LAB\_LOINC  
PRIORITY  
RESULT\_LOC  
LAB\_PX  
LAB\_PX\_TYPE  
LAB\_ORDER\_DATE  
SPECIMEN\_DATE  
SPECIMEN\_TIME  
**RESULT\_DATE**  
RESULT\_TIME  
RESULT\_QUAL  
RESULT\_NUM  
RESULT\_MODIFIER  
RESULT\_UNIT  
NORM\_RANGE\_LOW  
NORM\_MODIFIER\_LOW  
NORM\_RANGE\_HIGH  
NORM\_MODIFIER\_HIGH  
ABN\_IND

## PRESCRIBING

**PRESCRIBINGID**  
**PATID**  
ENCOUNTERID (optional)  
RX\_PROVIDERID  
RX\_ORDER\_DATE  
RX\_ORDER\_TIME  
RX\_START\_DATE  
RX\_END\_DATE  
RX\_QUANTITY  
RX\_REFILLS  
RX\_DAYS\_SUPPLY  
RX\_FREQUENCY  
RX\_BASIS  
RXNORM\_CUI

## PCORNET\_TRIAL

**PATID**  
**TRIALID**  
**PARTICIPANTID**  
TRIAL\_SITEID  
TRIAL\_ENROLL\_DATE  
TRIAL\_END\_DATE  
TRIAL\_WITHDRAW\_DATE  
TRIAL\_INVITE\_CODE

Associations with PCORnet clinical trials

## HARVEST

**NETWORKID**  
NETWORK\_NAME  
**DATAMARTID**  
DATAMART\_NAME  
DATAMART\_PLATFORM  
CDM\_VERSION  
DATAMART\_CLAIMS  
DATAMART\_EHR  
BIRTH\_DATE\_MGMT  
ENR\_START\_DATE\_MGMT  
ENR\_END\_DATE\_MGMT  
DISCHARGE\_DATE\_MGMT  
PX\_DATE\_MGMT  
RX\_ORDER\_DATE\_MGMT  
RX\_START\_DATE\_MGMT  
RX\_END\_DATE\_MGMT  
DISPENSE\_DATE\_MGMT  
LAB\_ORDER\_DATE\_MGMT  
SPECIMEN\_DATE\_MGMT  
RESULT\_DATE\_MGMT  
MEASURE\_DATE\_MGMT  
ONSET\_DATE\_MGMT  
REPORT\_DATE\_MGMT  
RESOLVE\_DATE\_MGMT  
PRO\_DATE\_MGMT  
REFRESH\_DEMOGRAPHIC\_DATE  
REFRESH\_ENROLLMENT\_DATE  
REFRESH\_ENCOUNTER\_DATE  
REFRESH\_DIAGNOSIS\_DATE  
REFRESH\_PROCEDURES\_DATE  
REFRESH\_VITAL\_DATE  
REFRESH\_DISPENSING\_DATE  
REFRESH\_LAB\_RESULT\_CM\_DATE  
REFRESH\_CONDITION\_DATE  
REFRESH\_PRO\_CM\_DATE  
REFRESH\_PRESCRIBING\_DATE  
REFRESH\_PCORNET\_TRIAL\_DATE  
REFRESH\_DEATH\_DATE  
REFRESH\_DEATH\_CAUSE\_DATE

Process-related data

<http://www.pcornet.org/resource-center/pcornet-common-data-model/>

**Bold font** indicates fields that cannot be null due to primary key definitions or record-level constraints.



The PCORnet CDM lives at

<http://pcornet.org/pcornet-common-data-model/>